Mutations in the KRAS gene can trigger the development of invasive HCC,41 and up-regulation of the KRAS pathway has been reported in patients with tumors that do not respond to PD-1 blocker therapy.42 The gene discussed is KRAS; the disease is hepatocellular carcinoma.